PF-Atlas › Clinical Trials › NCT02170025

Early Signs of Efficacy Study With Riociguat in Adult Homozygous Delta F508 Cystic Fibrosis Patients

Riociguat · Phase 2

Registry ID

NCT02170025

Phase

Phase 2

Status

Terminated

Drug / intervention

Riociguat (Adempas, BAY63-2521)

Sponsor

Bayer

Start

2014-09-30

About this trial

Riociguat is evaluated in NCT02170025, a Phase 2 idiopathic pulmonary fibrosis study sponsored by Bayer. Current status: Terminated.

View NCT02170025 on ClinicalTrials.gov →

Explore related

All Riociguat trials All IPF trials

Related trials

Riociguat — NCT02138825

Medical disclaimer. This page summarizes public trial data for NCT02170025 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.